SLC5A2 and type 2 diabetes mellitus: A collaborative meta-analysis that integrated the kidney outcomes from large placebo-controlled trials of SGLT-2 inhibitors from the SGLT-2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium concluded that in addition to the established cardiovascular benefits of SGLT-2 inhibitors, clinical evidence support their use for modifying risk of CKD progression and acute kidney injury, in patients with T2DM at high cardiovascular risk, and in patients with CKD or heart failure, irrespective of diabetes status, primary kidney disease or baseline kidney function.24